Literature DB >> 12039465

Risk of finding an endometrial cancer when atypical hyperplasia was incidentally diagnosed on hysteroscopic resection products.

Aubert Agostini1, Ludovic Cravello, Raha Shojai, Véronique Schaeffer, Florence Bretelle, Valérie Roger, Bernard Blanc.   

Abstract

OBJECTIVE: To evaluate the risk of discovering an endometrial cancer when atypical hyperplasia was diagnosed by histologic examination of hysteroscopic resection products. STUDY
DESIGN: A retrospective monocentric study from January 1994 to January 2001. Seventeen patients with atypical hyperplasia were included. Initial endometrial status was provided by operative hysteroscopy resection products. For all patients, there was no hysteroscopical aspect evocative of adenocarcinoma. Histopathological analysis of the hysterectomy pieces precised the final diagnosis.
RESULTS: Among the 17 hysterectomy pieces, one adenocarcinoma was diagnosed. Risk for discovering adenocarcinoma when atypical hyperplasia was diagnosed by operative hysteroscopy resection products was 5.9% (1/17).
CONCLUSION: Risk of omitting adenocarcinoma when atypical hyperplasia is discovered by hysteroscopy resection pieces is low.

Entities:  

Mesh:

Year:  2002        PMID: 12039465     DOI: 10.1016/s0301-2115(02)00005-2

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  2 in total

1.  Endometrial cancer arising from atypical complex hyperplasia: The significance in an endometrial biopsy and a diagnostic challenge.

Authors:  Jung Mi Byun; Dae Hoon Jeong; Young Nam Kim; En Bee Cho; Ju Eun Cha; Moon Su Sung; Kyung Bok Lee; Ki Tae Kim
Journal:  Obstet Gynecol Sci       Date:  2015-11-16

2.  Concurrent and future risk of endometrial cancer in women with endometrial hyperplasia: A systematic review and meta-analysis.

Authors:  Michelle T Doherty; Omolara B Sanni; Helen G Coleman; Chris R Cardwell; W Glenn McCluggage; Declan Quinn; James Wylie; Úna C McMenamin
Journal:  PLoS One       Date:  2020-04-28       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.